Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

15 Jun 2021 | 01:32 pm | 2 min. read

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

The pandemic has placed drug repurposing high on the agenda, with medications such as the steroid dexamethasone and rheumatoid arthritis treatment tocilizumab being used to treat patients severely ill with Covid-19.

Charities and patient groups seeking treatments for rare diseases are often particularly interested in the potential of new uses for existing drugs because they offer the possibility of lower overall costs and shorter timeframes to get treatments to patients and licensed medications already have known safety profiles.

The guide, Repurposing medicines: the opportunity and the challenges was launched today at the Findacure's virtual Drug Repurposing for Rare Diseases Conference 2021 and has a range of practical tips and advice for overcoming potential barriers including:

  • Seeking scientific advice from the regulator

  • Developing an intellectual property strategy

  • Collaborating with industry on drug repurposing opportunities

  • Taking steps to ensure medicines are made available to patients

Commenting on the report LifeArc CEO Dr Melanie Lee, CBE said:

The pandemic has shown what is possible in the field of drug repurposing. However, we know that not–for–profits and researchers can be confused by the complex commercial and regulatory challenges that repurposing presents. We want to improve awareness of those challenges so that applications for repurposing proceed smoothly – making it more likely that life-changing medicines will reach patients in the clinic. That translational science is LifeArc’s area of expertise – ensuring that successful lab research results in new treatments or therapies for patients as quickly as possible.”

Nicole Jadeja, life sciences partner at Pinsent Masons, said:

“We are delighted to have partnered with LifeArc on this important project and hope that this will provide practical advice to help convert more repurposing projects into new treatments for patients. One thing that really stands out is how important collaboration is in delivering on the promise of repurposing and drawing upon the experiences of the wide range of stakeholders in the guide."

The guide provides clear examples of the benefits of finding new uses for existing medicines including the repurposing of the breast cancer drug tamoxifen for treating X-linked myotubular myopathy (a rare neuromuscular disorder that mainly affects boys), using a vertigo drug as a treatment for certain rare and devastating neurodegenerative diseases and the successful repurposing of a drug called rapamycin which has transformed the lives of women with lymphangioleiomyomastosis (LAM).

Findacure CEO Dr Rick Thompson said:

"In the world of rare diseases, millions of patients live with no treatment. Drug repurposing offers a quick, cheap, accessible and patient-friendly route to develop new treatments for rare diseases, and in recent years the field has grown steadily. However, we must address roadblocks – including a lack of financial incentive for industry and a lack of regulatory knowledge in academia. We can't wait to get working with LifeArc to deliver change. COVID-19 has shown what can be achieved in repurposing with the right funding and government incentives. Now, those benefits must reach the world's 350 million rare disease patients."

Latest press releases

Show me all press releases

Pinsent Masons MPillay advises Ikigai Ventures Limited on its listing on the Official List (Main Board) of the London Stock Exchange

Multinational law firm Pinsent Masons MPillay has advised Ikigai Ventures Limited, a company acquiring target businesses that have a strong positive social impact and/or environmental, social and governance (ESG) strategy, on its admission to the Official List of the London Stock Exchange.

Pinsent Masons MPillay advises Fintech Asia Limited on its listing on the Official List (Main Board) of the London Stock Exchange

Multinational law firm Pinsent Masons MPillay has advised Fintech Asia Limited, a company acquiring target businesses in the fintech sector, on its admission to the Official List of the London Stock Exchange.

Pinsent Masons advises SOLA Group on renewable energy Power Purchase Agreement

Multinational law firm Pinsent Masons was appointed as sponsors legal counsel and advised South African energy company SOLA Group on its solar power initiative with Tronox, which will transform the manufacturing business’ electricity supply and support its 2050 net zero targets.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons appoints Martin Hayward as new technology partner in Dubai

Multinational law firm Pinsent Masons has launched its Middle Eastern Technology, Media Telecoms (TMT) offering with the hire of TMT partner Martin Hayward in the wake of significant developments for digitalisation in the region.

Pinsent Masons advises UMS Consulting on its acquisition by Expleo

Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.

Pinsent Masons advises climate-tech venture capital fund, Systemiq Capital, on the $70m closing of its second fund

Multinational law firm Pinsent Masons has advised climate-tech VC fund Systemiq Capital on the $70 million first close of its second fund, targeting $200 million to continue backing the best early-stage climate tech entrepreneurs.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts